Skip to main content

Table 2 Change in HIF-1α expression between primary tumor and recurrent tumor by ER/TAM group and time to recurrence among 269 recurrences from the ProBe CaRe population-based case control study

From: Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study

Characteristics

Change in HIF-1α expressiona

Decrease

No change

Increase

n

%

n

%

n

%

Total

76

(28)

130

(48)

63

(23)

Median change [IQR]

− 18.2 [− 44.2, − 8.0]

 

0 [− 1.3, 1.3]

 

21.3 [9.5, 54]

 

ER/TAM group

ER+/TAM+

41

(25)

84

(51)

38

(23)

ER−/TAM−

35

(33)

46

(43)

25

(24)

HIF-1α category

Positive

63

(79)

2

(2.5)

15

(19)

Negative

13

(6.9)

128

(68)

48

(25)

Time to recurrence, years

1 to < 2

30

(31)

43

(45)

23

(24)

2 to < 3

12

(21)

32

(56)

13

(23)

3 to < 4

7

(16)

26

(58)

12

(27)

4 to < 6

17

(37)

18

(39)

11

(24)

6–10

10

(40)

11

(44)

4

(16)

  1. ER, estrogen receptor; HIF-1α, hypoxia-inducible factor 1; IQR, interquartile range; TAM, tamoxifen